Compare Abbott Laboratories (ABT) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Abercrombie & Fitch Co. — how do they compare? Abbott Laboratories trades at $110.22 (market cap $187.95B), while Abercrombie & Fitch Co. trades at $113.62 (market cap $5.24B). The key difference: Abbott Laboratories is far larger — about 35.9× Abercrombie & Fitch Co.'s market cap, and Abbott Laboratories pays a 2.32% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ABT | ANF | |
|---|---|---|
Market Cap | $187.95B | $5.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $129.85 |
52-Week Low | $82.57 | $65.61 |
Enterprise Value | $214.96B | $5.91B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
ANF trades at $118.53, up 5.25% today, reflecting strong momentum. The stock exhibits bullish technical signals with support at $114 and resistance at $121. Fundamentally, the company reported robust earnings, with Q1 2026 EPS of $1.47 beating expectations of $1.28, and revenue growth from $4.3B in 2024 to $4.95B in 2025. Profitability metrics are solid, with a net income margin of 11.44% in 2025 and ROE of 39.04%.
Outlook is positive due to consistent earnings beats and strategic campaigns, but risks include market volatility and competitive pressures. Analysts are mixed with a consensus price target of $112.86, below the current price, suggesting potential overvaluation. Institutional interest is growing, with Amundi increasing its stake by 201.2% in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
